Joshua Sabari, MD

thoracic medical oncologist

NYU Langone

Published Articles (1)

EGFR Resistance Is Genuinely Heterogeneous, and That Should Change How We Study New Drugs

September 3, 2026

Resistance to third-generation EGFR inhibitors is far more heterogeneous than the resistance patterns seen after earlier-generation drugs, and in 40-50% of patients, no single resistance mechanism can even be identified.